Company Description

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases.

It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy.

The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024.

Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Climb Bio, Inc.

Country	United States
Founded	2018
IPO Date	Aug 10, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	11
CEO	Aoife Brennan

Contact Details

Address: PMB #117, 2801 Centerville Road, 1st Floor Wilmington, Delaware 19808-1609 United States
Phone	866 857 2596
Website	eliemtx.com

Stock Details

Ticker Symbol	CLYM
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001768446
ISIN Number	US28658R1068
Employer ID	83-2273741
SIC Code	2834

Key Executives

Name	Position
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc	Chief Executive Officer, President and Director
Dr. Brett Kaplan M.B.A., M.D.	Chief Operating Officer and Principal Financial Officer
Emily Pimblett	Chief Accounting Officer
Jo Palmer-Phillips Ph.D.	Chief Development Officer
Dr. Nishi Rampal M.D.	Senior Vice President of Clinical Development

Latest SEC Filings

Date	Type	Title
Nov 22, 2024	EFFECT	Notice of Effectiveness
Nov 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024	S-3	Registration statement under Securities Act of 1933
Nov 12, 2024	8-K	Current Report
Nov 12, 2024	10-Q	Quarterly Report
Oct 15, 2024	8-K	Current Report
Oct 2, 2024	8-K	Current Report
Aug 27, 2024	8-K	Current Report
Aug 26, 2024	8-K	Current Report
Aug 16, 2024	SC 13D/A	[Amend] General statement of acquisition of beneficial ownership

View All SEC Filings